Although graft-versus-leukemia effects in allogeneic bone marrow transplantation (alloBMT) are well documented, graft-versus-tumor (GVT) effects are poorly defined. To investigate the latter, we established a murine model of breast cancer using TS/A, a transforming growth factor (TGF)-β1-secreting breast cancer cell line of BALB/c origin. In the setting of disparate (parent into F1) alloBMT, no appreciable GVT was identified. To assess whether TGF-β1 secreted by the tumor might inhibit the antitumor response, TGF-β1 antisense vector was transfected into the TS/A breast cancer cell line. Mice were inoculated with either TGF-β1 antisense transfected or the mock transfected cell line and underwent syngeneic or alloBMT. No evidence of GVT was appreciated for the mock-transfected breast cancer cell line as assessed by an absence of a statistically significant difference in survival between syngeneic and alloBMT groups. However, there was a highly statistically significant survival difference between allogeneic versus syngeneic bone marrow transplantation groups inoculated with the TGF-β1 antisense-transfected cell line (P = .00001) as well as when comparing the survival of mice that received alloBMT for TGF-β1 antisense-transfected tumor versus mock-transfected tumor (P = .0008). These data suggest that (1) GVT exists against the antisense-transfected breast cancer cells in this experimental model and (2) TGF-β1 may be involved in suppressing antitumor responses in the setting of alloBMT for breast cancer.
- Breast cancer
ASJC Scopus subject areas